|Description||GNE-9605 retained excellent predicted human metabolic stability when assayed in human liver microsomes and hepatocytes. In addition, no reversible or time-dependent inhibition of any of the major CYP isoforms was observed. The demonstrated metabolic stability, brain penetration across multiple species, and selectivity of these inhibitors support their use in preclinical efficacy and safety studies.|
|Appearance||white to off-white solid powder|
|Synonyms||GNE9605; GNE 9605|
GNE-9605 retained excellent predicted human metabolic stability when assayed in human liver microsomes and hepatocytes. In addition, no reversible or time-depen...
JH-II-127, a Pyrrolopyrimidine derivative, is a highly potent, selective, and brain penetrant LRRK2 inhibitor, of both wild-type and G2019S mutant LRRK2. IC50: ...
Potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively). Atte...
LRRK2-IN-1 is a benzodiazepine based derivative and is known as a selective inhibitor of the Parkinson's disease kinase LRRK2.
PF06447475 is a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Leucine rich repeat kinase 2 (LRRK2) has been genetically ...
MLi-2 is a potent, orally available and brain penetrant inhibitor of LRRK2 (IC50= 0.76 nM) with excellent selectivity that shows >295-fold selectivity for over ...
CZC-25146 is a compound that acts as an inhibitor of LRRK2, a factor in the expression of Parkinsons’s disease, and is ATP-competitive.
HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM)<br /> <strong>IC50 Value</strong>: 23.3 nM ...
GSK2578215A induces a dose-dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and LRRK2[G2019S] stably transfected into HEK293 ce...
CZC-25146 is a compound that acts as an inhibitor of LRRK2, a factor in the expression of Parkinsons